Arkansas Pain Care Clinics, PA

Arkansas Pain Care Clinics, PA was paid $298K by Medicaid between Jan 2018 and Nov 2024, across 30 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 48% of everything it billed.

33Billing provider infoARKANSAS PAIN CARE CLINICS, PA
LITTLE ROCK, AR 72211

33aNPI1467962118assigned 10/09/2017

33bProvider typePain Medicine (Anesthesiology) Physician

28Total paid$298K

24GClaims28,010

24DCodes billed30

24AFirst – last monthJan 2018 – Nov 2024

Compared with peers

Next to other Pain Medicine (Anesthesiology) Physician providers in Arkansas

Rank by total paid#3 of 17

Median peer was paid$42K

This provider vs. median7.2×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	3,982	$55K
2019	4,230	$16K
2020	3,338	$22K
2021	3,644	$29K
2022	4,300	$58K
2023	4,439	$65K
2024incomplete	4,077	$53K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
99214	Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity	48%	8,019	5,034	$142K
99213	Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity	23%	6,302	3,884	$67K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	14%	6,161	4,668	$42K
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	7.2%	1,929	1,496	$22K
99215	Doctor's office visit, returning patient (complex)Prolong outpt/office vis	3.1%	306	201	$9K
99204	Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity	1.3%	131	70	$4K
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	1.2%	49	36	$4K
64493		<1%	82	41	$3K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	<1%	275	212	$2K
80306		<1%	77	51	$876.82
96127		<1%	1,158	736	$760.61
27096		<1%	28	13	$585.84

18 more codes

J1100	Injection, dexamethasone sodium phosphate, 1 mg	<1%	983	$446.34
99211	Office or other outpatient visit for the evaluation and management of an established patient, minimal severity	<1%	80	$395.54
64494		<1%	58	$229.75
96132		<1%	56	$195.05
64495		<1%	58	$165.00
96138		<1%	46	$52.29
G8427	Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications	<1%	261	$0.21
G9562	Patients who had a follow-up evaluation conducted at least every three months during opioid therapy	<1%	262	$0.21
G9578	Documentation of signed opioid treatment agreement at least once during opioid therapy	<1%	262	$0.21
G9584	Patient evaluated for risk of misuse of opiates by using a brief validated instrument (e.g., opioid risk tool, soapp-r) or patient interviewed at least once during opioid therapy	<1%	262	$0.21
G8730	Pain assessment documented as positive using a standardized tool and a follow-up plan is documented	<1%	262	$0.21
G8754	Most recent diastolic blood pressure < 90 mmhg	<1%	152	$0.14
G8752	Most recent systolic blood pressure < 140 mmhg	<1%	109	$0.10
G8753	Most recent systolic blood pressure >= 140 mmhg	<1%	31	$0.02
G8755	Most recent diastolic blood pressure >= 90 mmhg	<1%	16	$0.01
3288F		0%	260	$0.00
0518F		0%	260	$0.00
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	0%	75	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialARSHAD, MUHAMMAD (OWNER)